Risk Factors for Predicting Osteoporosis in Patients Who Receive Thyrotropin Suppressive Levothyroxine Treatment for Differentiated Thyroid Carcinoma

SOYDAL Ç., ÖZKAN E., Nak D., ELHAN A. H., KÜÇÜK N. Ö., KIR K. M.

MOLECULAR IMAGING AND RADIONUCLIDE THERAPY, cilt.28, sa.2, ss.69-75, 2019 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 28 Sayı: 2
  • Basım Tarihi: 2019
  • Doi Numarası: 10.4274/mirt.galenos.2019.89410
  • Dergi Adı: MOLECULAR IMAGING AND RADIONUCLIDE THERAPY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.69-75
  • Anahtar Kelimeler: Differentiated thyroid carcinoma, osteoporosis, thyroid-stimulating hormone suppression treatment, BONE-MINERAL DENSITY, HORMONE SUPPRESSION, CANCER, THERAPY, MANAGEMENT, FRACTURE, OUTCOMES
  • Ankara Üniversitesi Adresli: Evet

Özet

Objectives: Endogenous hyperthyroidism accelerates bone turnover and shortens the normal bone remodeling cycle, which results in reduced bone density. It is estimated that suppressive levothyroxine (LT4) therapy also decreases bone density. The aim of this study was to define risk factors for osteoporosis development in patients under thyrotropin-stimulating hormone (TSH) suppressive treatment for differentiated thyroid cancer (DTC).